
Microencapsulation vs Enteric Coating for Probiotics
How the delivery route you pick drives overage, cost per viable dose and format feasibility—before prototyping begins.
Read More →
How the delivery route you pick drives overage, cost per viable dose and format feasibility—before prototyping begins.
Read More →
Why strain count is the wrong starting point, and how to allocate CFU, overage and testing budget across a multi-strain blend.

Which ingredients can share a probiotic formula, which need a barrier, and which force two SKUs — decided before you pay for pilot samples.

Why the same lot can report different CFU counts, and how to turn method, sampling and stability data into contract terms you can verify.

Why CFU loss, batch drift and dose unevenness appear between sample and mass production — and how to audit a factory early.

Break down cost structures across probiotic dosage forms, avoid hidden fees, and choose the right OEM format to maximize your brand's profit...

Format is a formulation constraint: the same strain survives, decays and costs differently in a gummy than in a stick sachet.


Why end-of-shelf-life CFU, not release testing, should set your overage, packaging and stability data requirements.


Inside a GMP probiotic plant — fermentation, centrifugation, freeze-drying, blending and QC. What happens between the petri dish and your...

Stick sachets overtaking capsules, gut-brain claims rising, and new EU rules — what order books across Europe and North America tell us.